Pulmonary Hypertension SOLAR

Description

The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.

Conditions

Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension

Talk to us

Study Overview

On this page

Study Details

Study overview

The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.

Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH

Pulmonary Hypertension SOLAR

Condition
Interstitial Lung Disease
Intervention / Treatment

-

Contacts and Locations

Durham

Duke University Medical Center, Durham, North Carolina, United States, 27710

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age ≥ 18 years' old
  • 2. Be on the lung transplant waiting list at Duke University Medical Center.
  • 3. PH as defined by RHC - mPAP \> 20 mmHg, PVR \> 3 WU, PCWP \< 15 mmHg
  • 4. Groups defined as:
  • 5. Willing and able to give informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
  • 1. Moderate to severe heart disease (LVEF \< 45% or severe LV Hypertrophy).
  • 2. Sarcoidosis.
  • 3. Active cancer.
  • 4. Sickle cell anemia.
  • 5. Liver disease (Childs-Pugh class C).
  • 6. Prisoners and pregnant women will not be approached for the study.
  • 7. Inability to obtain consent.
  • 8. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine).
  • 9. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bastiaan Driehuys,

Sudarshan Rajagopal, MD, PhD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

2024-12-30